Seeking Alpha

JKenser

 
View as an RSS Feed
View JKenser's Articles BY TICKER:
  • Why Neuralstem Has Plenty Of Upside In The Short Term
     • Tue, Aug. 26 CUR 37 Comments

    Summary

    • Neuralstem concluded dosing of Phase 2 NSI-566 trial for ALS (6-month observation concludes trial).
    • Multiple late stage failures for ALS worth multiple times more than CUR.
    • The market has given no value to Neuralstem's other indications.
  • An Early Valuation Of Neuralstem's NSI-189 For MDD
       • Thu, Jun. 26 CUR 60 Comments

    Summary

    • Phase 1b shows early signs of safety and efficacy.
    • Neurogenesis theory of depression could be "the next big thing in MDD".
    • Market potential for NSI-189 is enormous and could grow exponentially with extraordinary results.
  • An Early Valuation Of Neuralstem's NSI566
    Fri, Feb. 28 CUR 224 Comments